At particle sizes between one and five microns, the rules governing bioavailability, absorption kinetics, and ingredient interaction change fundamentally. UFP500 is a processing platform built around that change — not around it as a marketing claim, but as a measurable, reproducible physical reality.
Conventional milling and grinding reduces particle size in the 100–500 micron range — enough to improve texture and homogeneity, but not enough to meaningfully alter the biophysics of absorption. The shift in behaviour begins somewhere between 10 and 20 microns, and becomes pronounced below 5 microns.
At 1–5 microns, three things change simultaneously. First, surface-area-to-volume ratio increases dramatically — a 5-micron particle has roughly 100× the relative surface area of a 500-micron particle, which directly governs dissolution rate and enzymatic contact. Second, mucosal penetration dynamics shift: particles below 5 microns can interact with intestinal epithelium at a fundamentally different level than larger particles, even before any lipid encapsulation or permeability enhancer is involved. Third, phagocytic uptake becomes relevant — macrophages and dendritic cells in the gut-associated lymphoid tissue are particle-size-sensitive in the 1–5 micron range.
These are not hypotheses. They are well-documented in the pharmaceutical literature on fine-particle APIs, and in the food science literature on nanoparticle and microparticle absorption. UFP500 applies the same physics to botanical and functional ingredient matrices — a category the pharma and food science communities have largely approached with far less rigour than synthetic actives.
The challenge is not the theory. It is achieving this particle range reliably, without heat, without solvents, and without destroying the very bioactive structures you are trying to preserve. That is where UFP500 operates.
UFP500 particle reduction does not improve bioavailability through a single mechanism — it affects several simultaneously. Understanding the distinct contributions matters for predicting which ingredient categories will respond most significantly.
The Noyes-Whitney equation governs dissolution rate: it is directly proportional to surface area. Reducing particle diameter by 100× increases surface area by 10,000× in equivalent mass. At 1–5 microns, poorly soluble compounds that would ordinarily require lipid formulation or solubilisation technology dissolve at physiologically relevant rates in aqueous media alone. This is particularly significant for hydrophobic polyphenols, terpenoids, and fat-soluble vitamins.
dC/dt = DA(Cs−C) / hVParticles in the 1–10 micron range move through the unstirred water layer at the intestinal epithelial surface more effectively than larger particles, which are subject to greater sedimentation and incomplete dispersion. This increases the concentration gradient driving passive diffusion, and prolongs the residence time of active compounds in the absorptive zone of the small intestine.
Peyer's patches and associated M-cells in the gut-associated lymphoid tissue show preferential uptake of particles in the 1–5 micron range. For botanical compounds with immunomodulatory activity — Boswellia boswellic acids, beta-glucans, certain polysaccharides — this pathway represents a route to systemic bioavailability that bypasses hepatic first-pass metabolism. The particle size sensitivity of this mechanism is well-documented in the oral vaccine delivery literature.
For glucosinolate-containing botanical systems — most critically broccoli sprout — the conversion of glucoraphanin to sulforaphane requires intimate contact between substrate and the enzyme myrosinase. At conventional particle sizes, this reaction is incomplete. UFP500 processing increases the contact surface between glucoraphanin-rich cells and myrosinase-containing cells, substantially improving conversion yield and the bioactive sulforaphane content of the processed material.
Glucoraphanin + Myrosinase → Sulforaphane + GlucoseUFP500 achieves ultra-fine particle reduction without heat, which is critical for enzymatically active and thermally sensitive compounds. Myrosinase is denatured above approximately 60°C. Polyphenol oxidation accelerates significantly above 40°C. Volatile terpene compounds are lost at even lower temperatures. Cold-process particle refinement preserves these structures through the full processing cycle — a category of benefit that conventional hot-milling and spray-drying cannot offer.
UFP500 processes natural materials across botanical, fungal, marine, cereal, and fruit categories on a continuous basis. What matters is not a list of ingredients — it is understanding what ultra-fine particle processing unlocks in each material class, and why that changes what is possible in the application it is destined for.
Aromatic herbs, resins, roots, and plant-derived bioactive fractions. Ultra-fine particle processing dramatically improves the accessibility of polyphenols, terpenoids, and volatile compounds that conventional processing leaves largely trapped inside plant cell wall structures.
Fresh, dried, and upcycled fruit fractions — including juice and processing industry side streams with significant residual bioactive value. Anthocyanins, ellagitannins, and carotenoid fractions respond strongly to ultra-fine particle processing, with cold-process preservation of oxidation-sensitive pigment fractions critical to outcome quality.
Malt, whole grain fractions, and cereal-derived enzyme systems. Ultra-fine particle processing changes how these materials behave in dough matrices, fermentation systems, and functional food formats — opening new textural, nutritional, and bioactive dimensions that conventional milling cannot reach.
Crustacean shell biomass, microalgae, and coastal botanical matrices — among the most structurally complex and underutilised bioactive sources available. Ultra-fine particle processing unlocks chitin fractions, marine polyphenols, and structurally complex carbohydrates that standard processing cannot efficiently access.
Medicinal and functional fungi with complex cell wall architecture that severely limits bioavailability in conventionally processed form. Ultra-fine particle processing disrupts cell walls mechanically — without heat or solvents — releasing beta-glucan, polysaccharide, and bioactive alkaloid fractions into a form the body can actually use.
UFP500 processes new materials on a continuous basis. The platform expands with every material that moves through it. If the scientific rationale is clear and the application context is a genuine fit, the conversation starts with a feasibility evaluation — not a capability checklist.
Answers to the questions that come up in every early conversation — honest, direct, and without regulatory overreach.
No. UFP500 produces particles in the 1–5 μm range (D50), with D10 below 1 μm and D90 below 10 μm. Nanotechnology is generally defined as particles below 100 nanometres (0.1 μm). UFP500-processed material sits well above that threshold and does not carry the regulatory, toxicological, or safety considerations associated with true nanoparticles. This is an important distinction — and one we take seriously.
Particle size distribution is measured by laser diffraction — the standard analytical method for this size range — and confirmed by scanning electron microscopy (SEM) where morphology matters. D10, D50, and D90 values are documented for every production run. Results are ingredient-specific and vary based on feedstock characteristics and application target.
UFP500 operates as a cold process — no heat is applied, and ambient temperature is maintained throughout. This is critical for enzymatically active materials (myrosinase is denatured above ~60°C), polyphenol-rich fractions (oxidation accelerates with heat), and volatile terpene compounds. Bioactive retention is assessed against incoming material reference values for each ingredient category processed.
No solvents. No additives. No carrier agents. UFP500 is a dry, mechanical process. The output is the input ingredient — at a fundamentally different particle scale. This clean-label characteristic is one of the platform's most commercially relevant properties, particularly for food, supplement, and veterinary applications where label simplicity matters.
It refers to the potential uplift in bioavailable fraction relative to the same ingredient processed conventionally — based on the surface area increase achieved at 1–5 μm particle scale (50–100× surface area increase drives substantially faster dissolution and improved absorption kinetics). The actual improvement observed in any specific application depends on the ingredient, the matrix, the delivery format, and the absorption pathway involved. We report what the physics predicts and what our materials demonstrate — not a universal claim. Application-specific validation is always the right next step.
No — and this is important. Particle size is a proxy for performance, not the end goal. What matters is how the processed material behaves in its intended application: dissolution rate in a liquid matrix, dispersion in a dough, absorption across a mucosal surface, enzymatic activity in a biological system. The optimal particle size for any given application is defined by the science of that application. UFP500 processing parameters are set accordingly — and validated through the application itself, not through particle size alone.
No. UFP500 is a processing platform — it improves how ingredients behave. Health and medical claims are the domain of the specific formulation, the application, and the regulatory framework governing that product in its market. BioFund's own research programmes (SENTINEL, companion animal oncology, circular bioeconomy) generate data that informs those claims through proper scientific process. We describe what the physics does. The biology is for the science to determine.
UFP500 is not an isolated processing technology — it is the operational foundation of BioFund's botanical and nutraceutical research pipeline. The science informing the platform is the same science driving BioFund's therapeutic development work.
BioFund's research strategy validates botanical ingredient concepts in companion animal models before human application — a rigorous, ethically aligned pathway that generates meaningful pharmacokinetic and safety data. UFP500-processed materials are the formulation core of this pipeline.
The SENTINEL firefighter nutrition programme uses UFP500-processed broccoli sprout, polyphenol fruit powders, Cordyceps militaris, and algal omega-3 as a cold-formed functional bar core — targeting the IARC Group 1 occupational carcinogen classification for firefighting. University of Guelph is the academic partner.
UFP500 processing is being applied to marine and agri-food side streams — including chitin-bearing materials and coastal botanicals — as part of BioFund's broader circular bioeconomy research. The particle reduction potential of these materials is under active investigation.
Beyond botanical processing, the UFP500 facility infrastructure supports BioFund's biosimilar and cell line platform development — providing the controlled manufacturing environment required for research-grade material production and partner demonstration runs.
UFP500° appears on products built on the ultra-fine particle processing standard documented on this site. RAFFINÉ and PURE are the founding mark holders. The science here is what the mark promises.